External reproducibility of PD-L1 IHC 22C3 pharmDX for cervical cancer at CPS ≥ 1 and CPS ≥ 10


Agilent Technologies, Inc., Carpinteria, CA, USA; Merck and Co., Inc., Kenilworth, NJ, USA

Background
Despite advancements in cervical cancer care, women with persistent, recurrent, or metastatic cervical cancer face difficult prognoses with limited treatment options. Recent results from clinical trials KEYNOTE-158 (NCT02628067) and KEYNOTE-826 (NCT03635567) have demonstrated clinically meaningful results in patients with recurrent or metastatic cervical cancer whose tumors express PD-L1 with a Combined Positive Score (CPS) ≥ 1. Here we give evidence of the reproducibility of PD-L1 expression determination in cervical cancer utilizing PD-L1 IHC 22C3 pharmDX at the CPS ≥ 1 and CPS ≥ 10 cutoffs.

Methods
External reproducibility studies tested the inter-site, intra-site, inter-observer, and intra-observer assay reproducibility for cervical cancer at CPS ≥ 1 and CPS ≥ 10. To test inter- and intra-site reproducibility, five replicate sets of a blinded and randomized cervical cancer specimen set were tested at each of the three external sites. For inter- and intra-observer reproducibility, three external sites evaluated one pre-stained set of cervical cancer specimens. Percent agreement was calculated using Negative Percent Agreement (NPA), Positive Percent Agreement (PPA), and Overall Percent Agreement (OA). Pre-specified acceptance criteria (AC) for all components of the analyses were ≥85.0% for the lower bound value of a 95% two-tailed percentile bootstrap confidence interval (CI) of each percent agreement point.

Results
At the CPS ≥ 1 cutoff: (i) inter- and intra-site NPA/PPA/OA met AC with point estimates (PE) ≥97.5% and CI lower bounds ≥94.7%, and (ii) inter- and intra-observer NPA/PPA/OA met AC with PE ≥98.1% and CI lower bounds ≥94.9%. At the CPS ≥ 10 cutoff: (i) inter- and intra-site NPA/PPA/OA met AC with PE ≥92.8% and CI lower bounds ≥86.7%, and (ii) inter- and intra-observer NPA/PPA/OA met AC, with PE ≥98.4% and CI lower bounds ≥95.9%.

Conclusions
This study demonstrates high external lab reproducibility of PD-L1 IHC 22C3 pharmDX with respect to expression determination in cervical cancer at CPS ≥ 1 and CPS ≥ 10 cutoffs.

Ethics Approval
The external reproducibility study was approved by WCG IRB, study numbers 1284639, 1284652, and 1284653.